RxDoctor Payments Data

Jose Acevedo-Valles, MD

Cardiovascular Disease · San Juan, PRNPI 1215933916

Payments from drug & device makers

$1,957in general payments, 2019–2025

Across 32 payments — averaging $61.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$377
  • E.r. Squibb & Sons, L.L.C.$268
  • Boston Scientific$264
  • AstraZeneca$250
  • Abbott$229
  • Amgen$116
  • plus $453 from 6 others

What the payments were for

  • Food & beverage$1,957100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,957 in reported general payments places this provider in the 40th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$8,728
Medicare patients
37
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$46,877
EliquisApixaban31$32,532
XareltoRivaroxaban18$24,849
EntrestoSacubitril/Valsartan12$22,719
Metoprolol Succinate114$2,397
SynthroidLevothyroxine Sodium20$2,217
Candesartan Cilexetil13$1,891
Rosuvastatin Calcium120$1,832
Losartan Potassium123$1,537
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide71$1,413
Atorvastatin Calcium93$1,173
Nifedipine ErNifedipine23$842
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide12$593
Carvedilol36$445
Doxazosin Mesylate16$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$377$46,87741 claims
NovartisEntresto$105$22,71912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →